Biozep AS

Is a science-based and innovative Norwegian biopharmaceutical company discovering and developing effective, safe, and affordable drugs for chronic eye diseases. Biozep focuses on eye diseases which lead to vision impairment and vision loss such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and dry eye disease (DED).

​​Our unique drug substances are  based on modified polyunsaturated fatty acids. We have more than 20 years of experience in improving the properties of polyunsaturated fatty acids by introducing novel structural elements thereby making them more active and drug-like.

Biozep has discovered a certain class of modified polyunsaturated fatty acids with great potential in treatment of chronic eye diseases. We have identified a lead compound, BIZ-101, based on its potent cell-protective and anti-inflammatory effects documented by convincing in vitro data. BIZ-101 in a non-aqueous formulation shows significant anti-inflammatory effects in an animal model of Dry Eye Disease,  outperforming Ikervis.